Trevena (NASDAQ:TRVN) Coverage Initiated by Analysts at StockNews.com

Equities research analysts at StockNews.com assumed coverage on shares of Trevena (NASDAQ:TRVN) in a research report issued on Sunday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Trevena Stock Up 2.3 %

TRVN stock opened at $3.98 on Friday. The stock has a market cap of $3.38 million, a price-to-earnings ratio of -1.49 and a beta of 1.03. Trevena has a 52-week low of $3.35 and a 52-week high of $25.75. The business has a fifty day moving average of $3.08 and a two-hundred day moving average of $1.31.

Trevena (NASDAQ:TRVN) last posted its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.01) EPS for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.36. The company had revenue of $0.33 million during the quarter. As a group, sell-side analysts anticipate that Trevena will post -32.25 EPS for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Trevena stock. Armistice Capital LLC bought a new position in shares of Trevena, Inc. (NASDAQ:TRVN) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 797,714 shares of the biopharmaceutical company’s stock, valued at approximately $576,000. Armistice Capital LLC owned approximately 4.61% of Trevena as of its most recent SEC filing. Hedge funds and other institutional investors own 13.56% of the company’s stock.

Trevena Company Profile

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.